BIOAQ BioAmber

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against BioAmber Inc.

NEW YORK--(BUSINESS WIRE)--

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of BioAmber Inc. (NYSE: BIOA) resulting from allegations that BioAmber may have issued materially misleading business information to the investing public.

On March 16, 2017, BioAmber during after hours trading announced disappointing financial results for the 2016 fiscal year, missing its previously issued revenue guidance by $1.3 million. On an earnings conference call, President Fabrice Orecchioni of BioAmber, attributed the poor results to “pricing pressures” and “a disruption from a large customer that was expected to purchase 2.8 million of succinic acid in Q4 2016, but due to a technical problem in its manufacturing facility postponed the order to 2017.” On this news, shares of BioAmber fell sharply during intraday trading on March 17, 2017.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by BioAmber investors. If you purchased shares of BioAmber please visit the firm’s website at http://www.rosenlegal.com/cases-1089.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

EN
17/03/2017

Underlying

BIOAQBioAmber

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioAmber

Free Trial
BIOAQ BIOAMBER

Six Directors bought 219,998 shares at 0.750USD.

Six Directors at Bioamber Inc bought 219,998 shares at 0.750USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

08/17/17 August 17, 2017 1 EN
 PRESS RELEASE
Free
BIOAQ BIOAMBER

DEADLINE ALERT: Brower Piven Alerts Shareholders of Approaching Deadli...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of purchasers of BioAmber Inc. (NYSE: BIOA) (BioAmber or the “Company”) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 and/or on the open market from January 23, 2017 through March 16, 2017, inclusive (the “Class Period”). Investors who w...

May 9, 2017 1 EN
 PRESS RELEASE
Free
BIOAQ BIOAMBER

BIOA Investors: GPM Reminds Investors of the May 17 Deadline in the Cl...

LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the May 17, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased BioAmber Inc. (“BioAmber” or the “Company”) (NYSE: BIOA) securities (1) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 (the “Offering”); and/or (2) between January 23, 2017 and March 16, 2017, inclusive (the “Class Period”). BioAmber investors have until May 17, 2017 t...

May 9, 2017 1 EN
 PRESS RELEASE
Free
BIOAQ BIOAMBER

The Law Offices of Howard G. Smith Announces the Filing of a Securitie...

BENSALEM, Pa.--(BUSINESS WIRE)-- Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased BioAmber Inc. (“BioAmber” or the “Company”) (NYSE: BIOA) securities (1) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 (the “Offering”); and/or (2) between January 23, 2017 and March 16, 2017, inclusive (the “Class Period”). BioAmber investors have until May 17, 2017 to file a lead plaintiff motion. Investors suffering l...

April 13, 2017 1 EN
 PRESS RELEASE
Free
BIOAQ BIOAMBER

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses I...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of purchasers of BioAmber Inc. (NYSE: BIOA) (BioAmber or the “Company”) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 and/or on the open market from January 23, 2017 through March 16, 2017, inclusive (the “Class Period”). Investors who w...

April 3, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch